Ralliant Corporation (NYSE:RAL - Get Free Report) SVP Karen Bick sold 6,062 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the completion of the sale, the senior vice president owned 31,668 shares in the company, valued at approximately $2,280,096. This trade represents a 16.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ralliant Price Performance
RAL stock opened at $69.42 on Wednesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. The firm has a 50 day moving average price of $68.94 and a 200-day moving average price of $55.70. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The firm has a market capitalization of $7.68 billion, a price-to-earnings ratio of -6.40, a PEG ratio of 2.69 and a beta of 1.61.
Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities research analysts forecast that Ralliant Corporation will post 2.87 EPS for the current fiscal year.
Ralliant Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant's payout ratio is currently -1.84%.
Institutional Investors Weigh In On Ralliant
Several institutional investors have recently modified their holdings of RAL. Danske Bank A S bought a new stake in Ralliant in the 4th quarter worth about $25,000. Dunhill Financial LLC bought a new position in Ralliant during the 2nd quarter valued at about $25,000. Allworth Financial LP boosted its holdings in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company's stock valued at $26,000 after acquiring an additional 293 shares during the last quarter. Palisade Asset Management LLC purchased a new stake in shares of Ralliant during the 3rd quarter valued at about $26,000. Finally, BOKF NA bought a new stake in shares of Ralliant in the third quarter worth approximately $29,000.
Wall Street Analyst Weigh In
RAL has been the topic of several recent analyst reports. Citigroup increased their price objective on shares of Ralliant from $81.00 to $82.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Wall Street Zen cut shares of Ralliant from a "strong-buy" rating to a "buy" rating in a report on Tuesday, August 11th. Vertical Research downgraded shares of Ralliant from a "buy" rating to a "hold" rating and set a $65.00 target price on the stock. in a research note on Wednesday, May 27th. Oppenheimer increased their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an "outperform" rating in a report on Wednesday, May 13th. Finally, Barclays raised their price target on shares of Ralliant from $52.00 to $67.00 and gave the company an "overweight" rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $75.70.
View Our Latest Stock Report on RAL
About Ralliant
(
Get Free Report)
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
